Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction
2011

Toxicity of Capecitabine and Oxaliplatin in Colorectal Cancer

Sample size: 400 publication Evidence: moderate

Author Information

Author(s): Baird R, Biondo A, Chhaya V, McLachlan J, Karpathakis A, Rahman S, Barbachano Y, Cunningham D, Chau I

Primary Institution: Royal Marsden Hospital, London & Surrey, UK

Hypothesis

Does reducing the dose of capecitabine from 2000 mg/m² to 1700 mg/m² decrease toxicity in colorectal cancer patients?

Conclusion

Reducing the capecitabine dose did not significantly change the rates of gastrointestinal toxicities or hospitalizations.

Supporting Evidence

  • 400 patients were analyzed, with 200 receiving each dose of capecitabine.
  • No significant differences in severe diarrhoea rates were found between the two doses.
  • Neutropenia and liver dysfunction were significantly reduced with the lower dose.
  • Hospitalization rates due to toxicities were similar for both doses.

Takeaway

Doctors tried giving a lower dose of a cancer drug to see if it would make patients feel better, but it didn't really help.

Methodology

Retrospective analysis comparing toxicities before and after a dose reduction of capecitabine.

Potential Biases

Potential bias due to the non-randomized nature of the study and reliance on medical records.

Limitations

The study was retrospective and based on routine clinical practice rather than a controlled trial.

Participant Demographics

Median age was 65 years, with 59% male and 41% female participants.

Statistical Information

P-Value

P=0.80 for grades 3 and 4 diarrhoea, P<0.0001 for elevated bilirubin.

Digital Object Identifier (DOI)

10.1038/sj.bjc.6605995

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication